Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 10,579,284 shares, a decline of 17.3% from the November 15th total of 12,789,144 shares. Based on an average trading volume of 866,232 shares, the short-interest ratio is currently 12.2 days. Approximately 10.3% of the company’s stock are short sold.

Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at $10.44 on Thursday. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09. Lexicon Pharmaceuticals has a twelve month low of $8.07 and a twelve month high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The business had revenue of $26.94 million during the quarter, compared to analysts’ expectations of $27.97 million. During the same period in the previous year, the company earned ($0.35) earnings per share. The business’s revenue for the quarter was down 2.8% compared to the same quarter last year. analysts expect that Lexicon Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Several research analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, October 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a report on Sunday, September 17th. Finally, Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $28.50.

In other news, CEO Lonnel Coats bought 10,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was acquired at an average cost of $9.91 per share, with a total value of $99,100.00. Following the completion of the acquisition, the chief executive officer now owns 42,985 shares of the company’s stock, valued at $425,981.35. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Public Equities L.P. Invus bought 575,946 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was purchased at an average cost of $9.64 per share, with a total value of $5,552,119.44. The disclosure for this purchase can be found here. Insiders have purchased 945,353 shares of company stock worth $9,304,953 in the last three months. 5.77% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP raised its holdings in shares of Lexicon Pharmaceuticals by 158.0% during the third quarter. GSA Capital Partners LLP now owns 50,786 shares of the biopharmaceutical company’s stock valued at $624,000 after purchasing an additional 31,100 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Lexicon Pharmaceuticals during the third quarter valued at approximately $149,000. Stifel Financial Corp raised its holdings in shares of Lexicon Pharmaceuticals by 12.3% during the third quarter. Stifel Financial Corp now owns 80,419 shares of the biopharmaceutical company’s stock valued at $987,000 after purchasing an additional 8,833 shares during the last quarter. Pinnacle Associates Ltd. raised its holdings in shares of Lexicon Pharmaceuticals by 25.5% during the third quarter. Pinnacle Associates Ltd. now owns 897,045 shares of the biopharmaceutical company’s stock valued at $11,025,000 after purchasing an additional 182,215 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of Lexicon Pharmaceuticals by 5.6% during the third quarter. Schwab Charles Investment Management Inc. now owns 204,129 shares of the biopharmaceutical company’s stock valued at $2,509,000 after purchasing an additional 10,811 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/14/short-interest-in-lexicon-pharmaceuticals-inc-lxrx-decreases-by-17-3.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.